drugset

drugset / Trial / NCT05102292

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

NCT05102292 ↗

Phase 1/2 Unknown 25 enrolled Shanghai Henlius Biotech

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).

Timeline

Start: 2021-12-10
Primary completion: 2024-06-30
Completion: 2024-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HLX208	Unknown	450 mg	Oral

Indications